OTC · Healthcare

Emmaus Life Sciences, Inc. (EMMA)

As-reported financials and recent SEC filings for Emmaus Life Sciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$12.5M

Net income

$-7.5M

Net margin

-60.2%

Diluted EPS

$-0.12

ROE

11.8%

P/E (TTM)

—

Market cap

—

Debt / equity

-0.4×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$12.5M	$16.7M	$29.6M	$18.4M	$20.6M
Gross profit	—	—	—	$15.8M	$17.3M
Operating income	$231,000	$-1.9M	$3.5M	$-6.6M	$-6.1M
Net income	$-7.5M	$-6.5M	$-3.7M	$-10.6M	$-15.9M
Diluted EPS	$-0.12	$-0.10	$-0.07	$-0.21	$-0.32

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-05-15

10-Q2026-05-15

32026-04-21

8-K2026-04-17

8-K2026-04-14

8-K2026-03-31

10-K2026-03-31

8-K2026-03-04

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on EMMA

Search Emmaus Life Sciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.